Cargando…

Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial

BACKGROUND: The Cytosponge is a cell-collection device, which, coupled with a test for trefoil factor 3 (TFF3), can be used to diagnose Barrett’s oesophagus, a precursor condition to oesophageal adenocarcinoma. BEST3, a large pragmatic, randomised, controlled trial, investigated whether offering the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghimire, Bhagabati, Landy, Rebecca, Maroni, Roberta, Smith, Samuel G., Debiram-Beecham, Irene, Sasieni, Peter D., Fitzgerald, Rebecca C., Rubin, Greg, Walter, Fiona M., Waller, Jo, Offman, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832657/
https://www.ncbi.nlm.nih.gov/pubmed/36627580
http://dx.doi.org/10.1186/s12876-022-02630-1
_version_ 1784868098044592128
author Ghimire, Bhagabati
Landy, Rebecca
Maroni, Roberta
Smith, Samuel G.
Debiram-Beecham, Irene
Sasieni, Peter D.
Fitzgerald, Rebecca C.
Rubin, Greg
Walter, Fiona M.
Waller, Jo
Offman, Judith
author_facet Ghimire, Bhagabati
Landy, Rebecca
Maroni, Roberta
Smith, Samuel G.
Debiram-Beecham, Irene
Sasieni, Peter D.
Fitzgerald, Rebecca C.
Rubin, Greg
Walter, Fiona M.
Waller, Jo
Offman, Judith
author_sort Ghimire, Bhagabati
collection PubMed
description BACKGROUND: The Cytosponge is a cell-collection device, which, coupled with a test for trefoil factor 3 (TFF3), can be used to diagnose Barrett’s oesophagus, a precursor condition to oesophageal adenocarcinoma. BEST3, a large pragmatic, randomised, controlled trial, investigated whether offering the Cytosponge-TFF3 test would increase detection of Barrett’s. Overall, participants reported mostly positive experiences. This study reports the factors associated with the least positive experience. METHODS: Patient experience was assessed using the Inventory to Assess Patient Satisfaction (IAPS), a 22-item questionnaire, completed 7–14 days after the Cytosponge test. STUDY COHORT: All BEST3 participants who answered ≥ 15 items of the IAPS (N = 1458). STATISTICAL ANALYSIS: A mean IAPS score between 1 and 5 (5 indicates most negative experience) was calculated for each individual. ‘Least positive’ experience was defined according to the 90th percentile. 167 (11.4%) individuals with a mean IAPS score of ≥ 2.32 were included in the ‘least positive’ category and compared with the rest of the cohort. Eleven patient characteristics and one procedure-specific factor were assessed as potential predictors of the least positive experience. Multivariable logistic regression analysis using backwards selection was conducted to identify factors independently associated with the least positive experience and with failed swallow at first attempt, one of the strongest predictors of least positive experience. RESULTS: The majority of responders had a positive experience, with an overall median IAPS score of 1.7 (IQR 1.5–2.1). High (OR = 3.01, 95% CI 2.03–4.46, p < 0.001) or very high (OR = 4.56, 95% CI 2.71–7.66, p < 0.001) anxiety (relative to low/normal anxiety) and a failed swallow at the first attempt (OR = 3.37, 95% CI 2.14–5.30, p < 0.001) were highly significant predictors of the least positive patient experience in multivariable analyses. Additionally, sex (p = 0.036), height (p = 0.032), alcohol intake (p = 0.011) and education level (p = 0.036) were identified as statistically significant predictors. CONCLUSION: We have identified factors which predict patient experience. Identifying anxiety ahead of the procedure and discussing particular concerns with patients or giving them tips to help with swallowing the capsule might help improve their experience. Trial registration ISRCTN68382401. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02630-1.
format Online
Article
Text
id pubmed-9832657
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98326572023-01-12 Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial Ghimire, Bhagabati Landy, Rebecca Maroni, Roberta Smith, Samuel G. Debiram-Beecham, Irene Sasieni, Peter D. Fitzgerald, Rebecca C. Rubin, Greg Walter, Fiona M. Waller, Jo Offman, Judith BMC Gastroenterol Research BACKGROUND: The Cytosponge is a cell-collection device, which, coupled with a test for trefoil factor 3 (TFF3), can be used to diagnose Barrett’s oesophagus, a precursor condition to oesophageal adenocarcinoma. BEST3, a large pragmatic, randomised, controlled trial, investigated whether offering the Cytosponge-TFF3 test would increase detection of Barrett’s. Overall, participants reported mostly positive experiences. This study reports the factors associated with the least positive experience. METHODS: Patient experience was assessed using the Inventory to Assess Patient Satisfaction (IAPS), a 22-item questionnaire, completed 7–14 days after the Cytosponge test. STUDY COHORT: All BEST3 participants who answered ≥ 15 items of the IAPS (N = 1458). STATISTICAL ANALYSIS: A mean IAPS score between 1 and 5 (5 indicates most negative experience) was calculated for each individual. ‘Least positive’ experience was defined according to the 90th percentile. 167 (11.4%) individuals with a mean IAPS score of ≥ 2.32 were included in the ‘least positive’ category and compared with the rest of the cohort. Eleven patient characteristics and one procedure-specific factor were assessed as potential predictors of the least positive experience. Multivariable logistic regression analysis using backwards selection was conducted to identify factors independently associated with the least positive experience and with failed swallow at first attempt, one of the strongest predictors of least positive experience. RESULTS: The majority of responders had a positive experience, with an overall median IAPS score of 1.7 (IQR 1.5–2.1). High (OR = 3.01, 95% CI 2.03–4.46, p < 0.001) or very high (OR = 4.56, 95% CI 2.71–7.66, p < 0.001) anxiety (relative to low/normal anxiety) and a failed swallow at the first attempt (OR = 3.37, 95% CI 2.14–5.30, p < 0.001) were highly significant predictors of the least positive patient experience in multivariable analyses. Additionally, sex (p = 0.036), height (p = 0.032), alcohol intake (p = 0.011) and education level (p = 0.036) were identified as statistically significant predictors. CONCLUSION: We have identified factors which predict patient experience. Identifying anxiety ahead of the procedure and discussing particular concerns with patients or giving them tips to help with swallowing the capsule might help improve their experience. Trial registration ISRCTN68382401. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02630-1. BioMed Central 2023-01-10 /pmc/articles/PMC9832657/ /pubmed/36627580 http://dx.doi.org/10.1186/s12876-022-02630-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ghimire, Bhagabati
Landy, Rebecca
Maroni, Roberta
Smith, Samuel G.
Debiram-Beecham, Irene
Sasieni, Peter D.
Fitzgerald, Rebecca C.
Rubin, Greg
Walter, Fiona M.
Waller, Jo
Offman, Judith
Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial
title Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial
title_full Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial
title_fullStr Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial
title_full_unstemmed Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial
title_short Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trial
title_sort predictors of the experience of a cytosponge test: analysis of patient survey data from the best3 trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832657/
https://www.ncbi.nlm.nih.gov/pubmed/36627580
http://dx.doi.org/10.1186/s12876-022-02630-1
work_keys_str_mv AT ghimirebhagabati predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT landyrebecca predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT maroniroberta predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT smithsamuelg predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT debirambeechamirene predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT sasienipeterd predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT fitzgeraldrebeccac predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT rubingreg predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT walterfionam predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT wallerjo predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial
AT offmanjudith predictorsoftheexperienceofacytospongetestanalysisofpatientsurveydatafromthebest3trial